Description
Composition- Sitagliptin 100 mg + Pioglitazone 15 mg + Metformin 1000 mg
Mode of Action- Provides stronger triple-pathway diabetes management through DPP-4 inhibition, enhanced insulin sensitivity and suppression of hepatic glucose output.
USPs- High-strength triple diabetes therapy; effective in difficult glycemic control; broad metabolic support.
Prescribing Specialties- Diabetologist, Internal Medicine
